Janssen Archives - Page 3 of 3 - Cardiac Vascular News

Tag: Janssen

Janssen Receives Positive CHMP Opinion to Expand INVOKANA® and VOKANAMET® Labelling to Include Positive Data on Cardiovascular Morbidity and Mortality

Coronary/Structural Heart August 2, 2018 by Ken Dropiewski 0 comments

BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has issued a positive opinion to update the INVOKANA® (canagliflozin) and VOKANAMET® (canagliflozin and […]

Continue Reading →

Janssen Collaborates with Premier Inc. on Unique Study to Improve Stroke Risk Management among Hospitalized Patients with Atrial Fibrillation

Neuro Rhythm April 5, 2017 by Ken Dropiewski 0 comments

NEWS PROVIDED BY Janssen Pharmaceuticals, Inc. | 03 Apr, 2017, 08:00 ET TITUSVILLE, N.J., April 3, 2017 /PRNewswire/ — Janssen Pharmaceuticals, Inc. (Janssen) today announced it has collaborated with Premier Inc. on the first and largest study of its kind to address […]

Continue Reading →

Tag: Janssen

Janssen Receives Positive CHMP Opinion to Expand INVOKANA® and VOKANAMET® Labelling to Include Positive Data on Cardiovascular Morbidity and Mortality

Janssen Collaborates with Premier Inc. on Unique Study to Improve Stroke Risk Management among Hospitalized Patients with Atrial Fibrillation

Recent

BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure

Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies

Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data

Popular

Subscribe to Blog via Email